



Image: Big in the system Autobal in the system Constrained in the system Image: Big in the system Image: Bi	Singapore	Day 1 January 28	Day	Day 3 January 30			Day 4 January 31			
Image: Name of the state of the st	(SGT)		Janua							
Month And Section And Section <th< th=""><th></th><th></th><th>Antibody Immunot</th><th>therapy Locoregional/Oligo</th><th>Immuno-Biology</th><th>Screening/ED</th><th>Nursing/AHP</th><th>Palliative Care</th><th>Risk Reduction and Tobacco Control</th><th>Staging</th></th<>			Antibody Immunot	therapy Locoregional/Oligo	Immuno-Biology	Screening/ED	Nursing/AHP	Palliative Care	Risk Reduction and Tobacco Control	Staging
Concernance Service FUEL Instance Lange La					Pathology	Mesothelioma	Patient Advocacy	Targeted Therapies	SCLC/NET	Tumor Biology
Line GA Line GA Line GA Line GA Line GA 928 - 100 595 - County Sympositivity Syntaxistic Sint County Syntaxistic Sint County Syntaxistic<	07:00 - 09:00	Joint IASLC-CAALC-CSCO	PL02: Innovation to Bridge Lung Cancer Care Tomorrow			PS01: Presidential Symposium		PL04: A Vision for Clinical Trials in 2020 and Beyond		
Opps-topic DBS Contract Of Control Contro Control Control Control Cont	07.00 05.00	Session*	Live G	Live Q&A			Live Q&A			
D35 - 1130 D52 Induity Symposium D035 Promiting Attractory Symposium ES2 Plain Hellin Instance D037 Instance ES2 Plain Hellin Instance D037 Instance ES2 Plain Hellin Instance	09:15 - 10:15	ISO1: Satellite CME Symposium by	Systemic Therapies in Special Po After and New I Chemoimmunotherapy Established P	shed Drugs OA02: Updates in opulations Locally Advanced Drugs in NSCLC	ES09: Biomarkers in	ES10: Advances in Lung Cancer Screening Through Imaging and	ES11: Practice-Changing	ES20: Evidence Base for Symptom	ES21: The "How To" of	₩A09: Prognosis and Staging
10:30 - 13:0 0.002 Promiting December 2000 Promoting December 2000 Promiting December			Live G	Q&A Live Q&A	Live Q&A	Live Q&A	Live Q&A		Live Q&A	Live Q&A
Image: Construction of the second o	10:30 - 11:30	ISO2: Industry Symposium*	Antibody-Drug Need Biom Conjugate and Cytotoxic Guide the C Therapy in NSCLC Immunot	arkers to and Treating Choice of Oligometastatic herapy Diseases	OA07: Immuno-biology and Novel Immunotherapeutics	ES12: Public Health Issues in Lung Cancer		ES22: Quality of Life	Pandemic - Tobacco Control in the Prevention	ES23: Beyond the TNM
II:45-12.45 II:503: Industry Symposium MADD: Novel Systemic Training in NSCLC OAGE: Hot parts (IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII			Live Q&A	Live Q&A	Live Q&A			Live Q&A	Live Q&A	
Live G&A Live GAA Live	11:45 - 12:45	ISO3: Industry Symposium*		Alterations Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint	ES14: Novel Immunotherapy	MA05: Lung Cancer	Patient at the Center:	Managing Supportive		ES25: Unmet Need Issues of Current TNM
13:00 - 14:00 1504: Industry Symposium* 1506: Industry Symposium* 1500: Industry Symposium* 1510: Industry Symposium* 1512: Industry Symposium* 1513: Satellite CPD Symposium by ACE Oncoopy* 1514: Industry Symposium* 1515: Industry Symposium* <t< td=""><td></td><td></td><td>Live Q&A Live G</td><td></td><td></td><td>Live Q&A</td><td>Live Q&A</td><td>Live Q&A</td><td></td><td>Live Q&A</td></t<>			Live Q&A Live G			Live Q&A	Live Q&A	Live Q&A		Live Q&A
14:15 - 13:15 1505: Industry Symposium* Cases: Final Spring and Therapport Exists: Periodical Cases Treatment Cases: Final Spring and Therapport Exists: Periodical Cases Therapport Periodical Cases Therapport Exists: Periodical Cases Therapport Exists: Periodical Cases Therapport Exists: Periodical Cases Therappo	13:00 - 14:00	ISO4: Industry Symposium*	ISO8: Industry Symposium* ISO9: Industry S	Symposium* IS10: Industry Symposium*	IS11: Industry Symposium*	IS12: Industry Symposium*		IS13: Satellite CPD Symposium by		IS15: Industry Symposium*
15:30 - 16:30 ISO6: Industry Symposium* OAO5: Value and Quality in Lung Cancer ESO7: Pleural Effusion in a Cancer Patient MAO3: New and Revisited Factors in Early Stage Lung Cancer OAO9: Mesothelioma from Pathogenesis to Therapy and Progress MAO7: Improving Careford For People with Lung Cancer ES17: The New WHO OAO9: Mesothelioma from Pathogenesis to Therapy and Progress Sector Patient Progress OA11: A Symphony of Progress Progress Progress Next General Concerts Next Genera Concerts Next General Concerts	14:15 - 15:15	ISO5: Industry Symposium*	Cancer, from Screening to Treatment Lung Advances in E Imaging Therapeut Lung Ca	Diagnostics, g and tics for ancer	Genotyped: How Can We	Developments and Novel Treatments in Mesothelioma and Thymoma	Cancer Coalition/IASLC Session: Hot Topics for Advocates	Targetable Genetic Alterations in NSCLC	the Management of	ES27: Heterogeneity, Metastases and Resistance
Image: Control of the control of th	15:30 - 16:30	ISO6: Industry Symposium*	• CA05: Value and Quality ES07: Pleural	HEffusion in Revisited Factors in Early Stage	Classification of	OA09: Mesothelioma from Pathogenesis to	MA07: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New			€S29: Advances in
16:45 - 17:45 Iso7: Industry Symposium* Iso7: Industry Sym			Live Q&A	Live Q&A	Live Q&A	Live Q&A			Live Q&A	Live Q&A
	16:45 - 17:45	IS07: Industry Symposium*	the Real World Pulmonary	e Solitary Nodule OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy	Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non- Small Cell Lung Carcinoma	Immunotherapy in Unresectable	Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients	ES30: What is the Best Treatment Strategy to Target Rare Mutations	MA12: Controversies Old and New	MA13: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment
PLOS: Bench to Beasiale (Immunology) PSO2: Presidential Symposium (Rebroadcasted) PLOS: Affordable and Accessible Lung Cancer Care			*							
18:00 - 20:00 Session	18:00 - 20:00		PL03: Bench to Bedside (Immunology)		· · · · · · · · · · · · · · · · · · ·					
PL - Plenary PS - Presidential Symposium ES - Education Session OA - Oral Session MA - Mini Oral Session IS - Industry Symposium, Satellite CME Symposium 🛊 IASLC CME Accredited 🔅 CME or CPD Accredited by Other P				Live Q&A			Live Q&A			

PS - Presidential Symposium **ES - Education Session** OA - Oral Session PL - Plenarv *Not for CME Credit, see page 2 for more details for more information about the Industry Symposium sessions. **CME or CDP Accredited by Other Provider, see page 2 for more details.

IS - Industry Symposium, Satellite CME Symposium or Satellite CDP Symposium



IASLC ((1)) 2020 World Conference IASLC (1) 0n Lung Cancer Singapore PROGRAM AT A GLANCE VIRTUAL



Singapore (SGT)	Day 1 January 28	Day 2 January 29	Day 3 January 30	Day 4 January 31
07:00 - 09:00				
09:15 - 10:15	ISO1: Satellite CME Symposium by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer			
10:30 - 11:30	ISO2: Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC			
11:45 - 12:45	IS03: Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges			
13:00 - 14:00	ISO4: Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices	ISO8: Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIsISO9: Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLCISI0: Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO	IS11: Industry Symposium Sponsored by Amgen:IS12: Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC	IS13: Satellite CPDIS14: Industry Symposium Symposiumby ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent AdvancesIS14: Industry Symposium Sponsored by AstraZeneca: EVOlving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT PerspectiveIS15: Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing
14:15 - 15:15	ISO5: Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer			
15:30 - 16:30	ISO6: Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC			
16:45 - 17:45	IS07: Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer			
18:00 - 20:00				

These programs were approved by the IASLC 2020 World Conference on Lung Cancer Program Committee as independent activities held in conjunction with the IASLC 2020 World Conference on Lung Cancer. These programs are not sponsored or endorsed by IASLC and are not part of the official IASLC accredited program.

CME or CPD Accredited by Other Provider